Startseite Hybrid classical-Bayesian approach to sample size determination for two-arm superiority clinical trials
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Hybrid classical-Bayesian approach to sample size determination for two-arm superiority clinical trials

  • Valeria Sambucini EMAIL logo
Veröffentlicht/Copyright: 1. Juli 2024
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Traditional methods for Sample Size Determination (SSD) based on power analysis exploit relevant fixed values or preliminary estimates for the unknown parameters. A hybrid classical-Bayesian approach can be used to formally incorporate information or model uncertainty on unknown quantities by using prior distributions according to the Bayesian approach, while still analysing the data in a frequentist framework. In this paper, we propose a hybrid procedure for SSD in two-arm superiority trials, that takes into account the different role played by the unknown parameters involved in the statistical power. Thus, different prior distributions are used to formalize design expectations and to model information or uncertainty on preliminary estimates involved at the analysis stage. To illustrate the method, we consider binary data and derive the proposed hybrid criteria using three possible parameters of interest, i.e. the difference between proportions of successes, the logarithm of the relative risk and the logarithm of the odds ratio. Numerical examples taken from the literature are presented to show how to implement the proposed procedure.


Corresponding author: Valeria Sambucini, Dipartimento di Scienze Statistiche, Sapienza University of Rome, Piazzale Aldo Moro n. 5, 00185 Roma, Italy, E-mail: 

  1. Research ethics: Not applicable.

  2. Author contributions: The author has accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: The author states no conflict of interest.

  4. Research funding: None declared.

  5. Data availability: Not applicable.

Appendix

A. Simulation procedure to obtain the average unconditional probability of correctly rejecting H 0

We need to specify n 2, r, α, θ S , θ D , n D , θ 1 prior , θ 2 prior , m 1 prior and m 1 prior and a high number B. Then, AUPCR H 0 π D , π 1 , π 2 can be obtained via simulation by performing the following steps:

  1. Simulate B values from π 1(θ 1), θ 1 i , i = 1 , , B .

  2. Simulate B values from π 2(θ 2), θ 2 i , i = 1 , , B .

  3. For i = 1, …, B, compute UPCR H 0 π D , k θ 1 i , θ 2 i .

  4. Approximate AUPCR H 0 π D , π 1 , π 2 with the arithmetic mean of the B values obtained in step 3.

B. Effect of using prior distributions instead of point estimates for θ 1 and θ 2

In Section 3.2, we showed how to construct the average unconditional probability of correctly rejecting H 0 by introducing two prior distributions for θ 1 and θ 2 in order to avoid the use of the point estimates θ ̂ 1 and θ ̂ 2 , that affect both UPCR H 0 π D and CPCR H 0 ( θ D ) . More specifically, we considered two beta prior distributions, π j (θ j ) = beta(θ j ; α j , β j ), for j = 1, 2, and suggested to choose their hyperparameters by exploiting the expressions in (6). The effect of these prior densities on AUPCR H 0 π D , π 1 , π 2 depends on how they impact on the sample variance of the estimator Y n 2 , i.e. on σ Y n 2 2 ( θ 1 , θ 2 ) = k ( θ 1 , θ 2 ) 2 / n 2 .

When using the conditional and unconditional powers in (2) and (4), the sample variance is replaced by its plug-in estimate: all else being equal, the higher σ Y n 2 2 ( θ ̂ 1 , θ ̂ 2 ) , the lower the powers and, consequently, the larger the optimal sample sizes. Assuming that θ 1 and θ 2 are random variables that follow the beta distributions mentioned above, we can evaluate through simulation the characteristics of the corresponding distribution of the random quantity k(θ 1, θ 2), using the following steps.

  1. Set B as a large number.

  2. Simulate B values from π 1(θ 1), θ 1 i , i = 1 , , B .

  3. Simulate B values from π 2(θ 2), θ 2 i , i = 1 , , B .

  4. For i = 1, …, B, compute k θ 1 i , θ 2 i and display the corresponding density plot.

We can also approximate the probability that k(θ 1, θ 2) is lower (or higher) than k ( θ ̂ 1 , θ ̂ 2 ) with the proportion of the B values obtained in step 3 which are lower (or higher) than k ( θ ̂ 1 , θ ̂ 2 ) . These computations are useful to explain the behaviour of AUPCR H 0 π D , π 1 , π 2 .

Let us consider again the example in Section 4.1 with θ = log(OR). For the three couples of beta prior distributions represented in Figure 2, we perform the steps above to obtain the corresponding distributions of k ( θ 1 , θ 2 ) = 1 r θ 1 ( 1 θ 1 ) + 1 θ 2 ( 1 θ 2 ) , with r = 1, whose density plots are given in the left panel of Figure 6. The empirical probabilities that k(θ 1, θ 2) is lower than k ( θ ̂ 1 , θ ̂ 2 ) = k ( 0.75 , 0.6 ) = 9.5 are 0.488, 0.466 and 0.383, when m 1 prior = m 2 prior are equal to 12, 6 and 2, respectively. Thus, when introducing the beta prior densities, the probability that the variance of Y n 2 exceeds the fixed one based on point estimates is higher than 0.5. In other words, the two beta prior distributions convey jointly the information that, for each value of n 2, the variance of the test statistic Y n 2 is most probably larger than its preliminarily estimated value. As a result, the curve of the average unconditional probability of correctly rejecting H 0 results to be lower than that of the corresponding UPCR H 0 π D , as we can see in Figure 2.

Figure 6: 
Left panel: Kernel density plots of k(θ
1, θ
2), with r = 1, when θ = log(OR) for different choices of the beta prior distributions of θ
1 and θ
2 (see example in Section 4.1). Right panel: Kernel density plots of k(θ
1, θ
2), with r = 2, when θ = log(RR) for different choices of the beta prior distributions of θ
1 and θ
2 (see example in Section 4.2).
Figure 6:

Left panel: Kernel density plots of k(θ 1, θ 2), with r = 1, when θ = log(OR) for different choices of the beta prior distributions of θ 1 and θ 2 (see example in Section 4.1). Right panel: Kernel density plots of k(θ 1, θ 2), with r = 2, when θ = log(RR) for different choices of the beta prior distributions of θ 1 and θ 2 (see example in Section 4.2).

We also consider the example provided in Section 4.2 with θ = log(RR). In this case k ( θ 1 , θ 2 ) = 1 θ 1 r θ 1 + 1 θ 2 θ 2 , with r = 2. In the right panel of Figure 6, we show the density plots of k(θ 1, θ 2) obtained through simulation, that correspond to the three couples of beta prior distributions represented Figure 4. The empirical probabilities that k(θ 1, θ 2) is lower than k ( θ ̂ 1 , θ ̂ 2 ) = k ( 0.004 , 0.015 ) = 190.2 are 0.872, 0.777 and 0.721, when m 1 prior = m 2 prior are equal to 30, 100 and 200, respectively. Therefore, with this choice of beta priors, we have quite low probability values that the variance of Y n 2 exceeds σ Y n 2 2 ( θ ̂ 1 , θ ̂ 2 ) . This leads to values of AUPCR H 0 π D , π 1 , π 2 larger than those of UPCR H 0 π D and the difference between the curves is more evident as the prior sample sizes of the beta prior densities decrease, as it is shown in Figure 4.

References

1. Spiegelhalter, DJ, Abrams, KR, Myles, JP. Bayesian approaches to clinical trials and health-care evaluation. New York: Wiley; 2004.10.1002/0470092602Suche in Google Scholar

2. Chuang-Stein, C. Sample size and the probability of a successful trial. Pharm Stat 2006;5:305–9. https://doi.org/10.1002/pst.232.Suche in Google Scholar PubMed

3. Wang, Y, Fu, H, Kulkarni, P, Kaiser, C. Evaluating and utilizing probability of study success in clinical development. Clin Trials 2013;10:407–13. https://doi.org/10.1177/1740774513478229.Suche in Google Scholar PubMed

4. Ciarleglio, MM, Arendt, CD, Makuch, RW, Peduzzi, PN. Selection of the treatment effect for sample size determination in a superiority clinical trial using a hybrid classical and bayesian procedure. Contemp Clin Trials 2015;41:160–71. https://doi.org/10.1016/j.cct.2015.01.002.Suche in Google Scholar PubMed

5. Spiegelhalter, DJ, Freedman, LS. A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. Stat Med 1986;5:1–13. https://doi.org/10.1002/sim.4780050103.Suche in Google Scholar PubMed

6. Rufibach, K, Burger, H, Abt, M. Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development. Pharm Stat 2016;15:438–46. https://doi.org/10.1002/pst.1764.Suche in Google Scholar PubMed

7. O’Hagan, A, Stevens, JW. Bayesian assessment of sample size for clinical trials of cost-effectiveness. Med Decis Making 2001;21:219–30. https://doi.org/10.1177/02729890122062514.Suche in Google Scholar

8. O’Hagan, A, Stevens, JW, Campbell, MJ. Assurance in clinical trial design. Pharm Stat 2005;4:187–201. https://doi.org/10.1002/pst.175.Suche in Google Scholar

9. Lan, KG, Wittes, JT. Some thoughts on sample size: a Bayesian-frequentist hybrid approach. Clin Trials 2012;9:561–9. https://doi.org/10.1177/1740774512453784.Suche in Google Scholar PubMed

10. Brutti, P, De Santis, F, Gubbiotti, S. Bayesian-frequentist sample size determination: a game of two priors. Metron 2014;72:133–51. https://doi.org/10.1007/s40300-014-0043-2.Suche in Google Scholar

11. Sambucini, V. Bayesian vs frequentist power functions to determine the optimal sample size: testing one sample binomial proportion using exact methods. In: Tejedor, JP, editor. Bayesian inference. IntechOpen; 2017:77–97 pp.10.5772/intechopen.70168Suche in Google Scholar

12. Kunzmann, K, Grayling, MJ, Lee, KM, Robertson, DS, Rufibach, K, Wason, JMS. A review of bayesian perspectives on sample size derivation for confirmatory trials. Am Stat 2021;75:424–32. https://doi.org/10.1080/00031305.2021.1901782.Suche in Google Scholar PubMed PubMed Central

13. Carroll, KJ. Decision making from phase II to phase III and the probability of success: reassured by “assurance”. J Biopharm Stat 2013;23:1188–200. https://doi.org/10.1080/10543406.2013.813527.Suche in Google Scholar PubMed

14. Chen, DG, Ho, S. From statistical power to statistical assurance: it’s time for a paradigm change in clinical trial design. Commun Stat Simul 2017;46:7957–71. https://doi.org/10.1080/03610918.2016.1259476.Suche in Google Scholar

15. Ciarleglio, MM, Arendt, CD. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and bayesian procedure. Trials 2017;18:83. https://doi.org/10.1186/s13063-017-1791-0.Suche in Google Scholar PubMed PubMed Central

16. Ciarleglio, MM, Arendt, CD. Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure. Stat Methods Med Res 2019;28:1852–78. https://doi.org/10.1177/0962280218776991.Suche in Google Scholar PubMed

17. Lachin, JM. Biostatistical methods: the assessment of relative risks, 2nd ed. Hoboken: Wiley; 2011.10.1002/9780470907412Suche in Google Scholar

18. Wasserman, LA. All of statistics: a concise course in statistical inference. New York: Springer Nature; 2004.10.1007/978-0-387-21736-9Suche in Google Scholar

19. Gubbiotti, S, De Santis, F. Classical and Bayesian power functions: their use in clinical trials. Biomed Stat Clin Epidemiol 2008;2:201–11.Suche in Google Scholar

20. Sambucini, V. A Bayesian predictive two-stage design for phase II clinical trials. Stat Med 2008;27:1199–224. https://doi.org/10.1002/sim.3021.Suche in Google Scholar PubMed

21. Matano, F, Sambucini, V. Accounting for uncertainty in the historical response rate of the standard treatment in single-arm two-stage designs based on Bayesian power functions. Pharm Stat 2016;15:517–30. https://doi.org/10.1002/pst.1788.Suche in Google Scholar PubMed

22. Eaton, ML, Muirhead, RJ, Soaita, AI. On the limiting behavior of the “probability of claiming superiority” in a Bayesian context. Bayesian Anal 2013;8:221–32. https://doi.org/10.1214/13-ba809.Suche in Google Scholar

23. Teramukai, S, Daimon, T, Zohar, S. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials. Stat Med 2012;31:4243–54. https://doi.org/10.1002/sim.5505.Suche in Google Scholar PubMed

24. Chow, SC, Shao, J, Wang, H. Sample size calculations in clinical research, 2nd ed. Boca Raton: Chapman & Hall/CRC; 2008.10.1201/9781584889830Suche in Google Scholar

25. Wang, H, Chow, SC, Li, G. On sample size calculation based on odds ratio in clinical trials. J Biopharm Stat 2013;12:471–83. https://doi.org/10.1081/bip-120016231.Suche in Google Scholar


Supplementary Material

This article contains supplementary material (https://doi.org/10.1515/ijb-2023-0050).


Received: 2023-04-20
Accepted: 2024-05-20
Published Online: 2024-07-01

© 2024 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Research Articles
  3. Random forests for survival data: which methods work best and under what conditions?
  4. Flexible variable selection in the presence of missing data
  5. An interpretable cluster-based logistic regression model, with application to the characterization of response to therapy in severe eosinophilic asthma
  6. MBPCA-OS: an exploratory multiblock method for variables of different measurement levels. Application to study the immune response to SARS-CoV-2 infection and vaccination
  7. Detecting differentially expressed genes from RNA-seq data using fuzzy clustering
  8. Hypothesis testing for detecting outlier evaluators
  9. Response to comments on ‘sensitivity of estimands in clinical trials with imperfect compliance’
  10. Commentary
  11. Comments on “sensitivity of estimands in clinical trials with imperfect compliance” by Chen and Heitjan
  12. Research Articles
  13. Optimizing personalized treatments for targeted patient populations across multiple domains
  14. Statistical models for assessing agreement for quantitative data with heterogeneous random raters and replicate measurements
  15. History-restricted marginal structural model and latent class growth analysis of treatment trajectories for a time-dependent outcome
  16. Revisiting incidence rates comparison under right censorship
  17. Ensemble learning methods of inference for spatially stratified infectious disease systems
  18. The survival function NPMLE for combined right-censored and length-biased right-censored failure time data: properties and applications
  19. Hybrid classical-Bayesian approach to sample size determination for two-arm superiority clinical trials
  20. Estimation of a decreasing mean residual life based on ranked set sampling with an application to survival analysis
  21. Improving the mixed model for repeated measures to robustly increase precision in randomized trials
  22. Bayesian second-order sensitivity of longitudinal inferences to non-ignorability: an application to antidepressant clinical trial data
  23. A modified rule of three for the one-sided binomial confidence interval
  24. Kalman filter with impulse noised outliers: a robust sequential algorithm to filter data with a large number of outliers
  25. Bayesian estimation and prediction for network meta-analysis with contrast-based approach
  26. Testing for association between ordinal traits and genetic variants in pedigree-structured samples by collapsing and kernel methods
Heruntergeladen am 15.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ijb-2023-0050/html
Button zum nach oben scrollen